Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11337414 | 1.00 | CFTR (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL24919838 | 1.00 | CFTR (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL23689571 | 1.00 | CFTR (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL16774716 | 0.98 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL24016025 | 0.89 | L3MBTL1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL15417856 | 0.89 | L3MBTL1 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL18737228 | 0.87 | L3MBTL1 (0.50) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL18638771 | 0.86 | L3MBTL1 (0.49) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL21005661 | 0.86 | L3MBTL1 (0.49) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL28166486 | 0.86 | L3MBTL1 (0.49) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023003862-A1 | CXCR4 MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20190055194-A1 | Azetidinimines as Carbapenemases Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-02-21 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9867372-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | KARYOPHARM THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-9428490-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CFTR 43/4885SLC6A2 1936/4885SLC6A4 2344/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | CFTR 2905/4885SLC6A2 4125/4885SLC6A4 4099/4885 |
| US-20170137430-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | CFTR 1221/4885SLC6A2 606/4885SLC6A4 1169/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CFTR 2905/4885SLC6A2 4125/4885SLC6A4 4099/4885 |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CFTR 183/4885SLC6A2 2036/4885SLC6A4 1946/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | CFTR 4528/4885SLC6A2 1390/4885SLC6A4 1517/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CFTR 2905/4885SLC6A2 4125/4885SLC6A4 4099/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | CFTR 1050/4885SLC6A2 2638/4885SLC6A4 1805/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | CFTR 456/4885SLC6A2 4804/4885SLC6A4 4779/4885 |
| US-11744826-B2 | Compounds and methods of treating retinal degeneration | ALDH1A2, PDE6D, PDE6C | CFTR 537/4885SLC6A2 1654/4885SLC6A4 2606/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | CFTR 4034/4885SLC6A2 4323/4885SLC6A4 4422/4885 |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | AADAT, SLC1A2, SLC1A1 | CFTR 3012/4885SLC6A2 48/4885SLC6A4 37/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | CFTR 976/4885SLC6A2 4880/4885SLC6A4 4873/4885 |
| US-20190055194-A1 | Azetidinimines as Carbapenemases Inhibitors | OXA1L, QDPR, PADI1 | CFTR 962/4885SLC6A2 4561/4885SLC6A4 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.